Drug Delivery: Furin-Mediated Sequential Delivery of Anticancer Cytokine and Small-Molecule Drug Shuttled by Graphene (adv. Mater. 6/2015)

Tian Jiang,Wujin Sun,Qiuwen Zhu,Nancy A. Burns,Saad A. Khan,Ran Mo,Zhen Gu

DOI: https://doi.org/10.1002/adma.201570035

IF: 29.4

2015-01-01

Advanced Materials

Abstract:Advanced MaterialsVolume 27, Issue 6 p. 958-958 Inside Front CoverFree Access Drug Delivery: Furin-Mediated Sequential Delivery of Anticancer Cytokine and Small-Molecule Drug Shuttled by Graphene (Adv. Mater. 6/2015) Tianyue Jiang, Tianyue Jiang State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009 China Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695 USASearch for more papers by this authorWujin Sun, Wujin Sun Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695 USA Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599 USASearch for more papers by this authorQiuwen Zhu, Qiuwen Zhu State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009 ChinaSearch for more papers by this authorNancy A. Burns, Nancy A. Burns Department of Chemical & Biomolecular Engineering, North Carolina State University, Raleigh, NC, 27695 USASearch for more papers by this authorSaad A. Khan, Saad A. Khan Department of Chemical & Biomolecular Engineering, North Carolina State University, Raleigh, NC, 27695 USASearch for more papers by this authorRan Mo, Corresponding Author Ran Mo State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009 China Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695 USA Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599 USASearch for more papers by this authorZhen Gu, Corresponding Author Zhen Gu Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695 USA Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599 USASearch for more papers by this author Tianyue Jiang, Tianyue Jiang State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009 China Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695 USASearch for more papers by this authorWujin Sun, Wujin Sun Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695 USA Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599 USASearch for more papers by this authorQiuwen Zhu, Qiuwen Zhu State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009 ChinaSearch for more papers by this authorNancy A. Burns, Nancy A. Burns Department of Chemical & Biomolecular Engineering, North Carolina State University, Raleigh, NC, 27695 USASearch for more papers by this authorSaad A. Khan, Saad A. Khan Department of Chemical & Biomolecular Engineering, North Carolina State University, Raleigh, NC, 27695 USASearch for more papers by this authorRan Mo, Corresponding Author Ran Mo State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009 China Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695 USA Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599 USASearch for more papers by this authorZhen Gu, Corresponding Author Zhen Gu Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695 USA Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599 USASearch for more papers by this author First published: 06 February 2015 https://doi.org/10.1002/adma.201570035Citations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract A cellular protease-mediated graphene-based nanosystem is developed on page 1021 by R. Mo, Z. Gu, and co-workers for the co-delivery of a membrane-associated cytokine (tumor-necrosis-factor-related apoptosisinducing ligand, TRAIL) and an intracellular-acting small-molecule drug (Doxorubicin, DOX). TRAIL and DOX can be sequentially released toward the plasma membrane and nucleus, respectively. Citing Literature Volume27, Issue6February 11, 2015Pages 958-958 RelatedInformation